NERV · Minerva Neurosciences Inc
United States · RS rating 9 · As of 2026-11-03
| Price | 2.35 USD |
|---|---|
| 1-day change | +0.2% |
| RS rating (overall / 1M / 3M / 12M) | 9 / 13 / 10 / 24 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 17 / 6 / 9 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -6986.1% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +70.9% |
| Market cap (USD) | $299.4M |